DURHAM, N.C. --(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224

DURHAM, N.C. --(BUSINESS WIRE)--Jun. 21, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a

- Precision to Receive $75 Million Upfront for a Single Target; Precision Eligible to Receive up to an Additional $1.4 Billion in Milestones and Tiered Royalties on Sales of Licensed Products - Precision to Develop a Single ARCUS ® Nuclease Designed for Safe and Efficient In Vivo Gene Insertion -